AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01821833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
Study NCT01821833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
Study NCT00415506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
Study NCT01667536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: 99mTc-MIP-1404
Description: A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
Study NCT03156348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pharmacist Care
Description: During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations.
Study NCT04296279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP014
Description: Falciparum Malaria Protein-14
Study NCT04296279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
Study NCT04026347 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vesair Balloon
Description: Indwelling, intravesical balloon
Study NCT04026347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vesair Balloon
Description: Indwelling, intravesical balloon
Study NCT04026347 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham balloon placement
Description: Sham balloon placement procedure
Study NCT04180748 — intervention group
Intervention type: OTHER
Intervention: fluorescence imaging with 405nm light
Description: Each group will have images taken with an Health Canada approved device to capture images under white light and 405nm fluorescence with an mCherry filter. These images will not be used for diagnostics and will be analyzed for features which correlate to identified microbes from 16S RNA analysis and traditional microbiological technique. Groups are self identified by participants in order to capture a diverse population.
Study NCT06450249 — intervention group
Intervention type: BEHAVIORAL
Intervention: Humanitude® Care Methodology (HCM) training sessions
Description: During a five-day training session healthcare professionals are trained to the HCM within their own care unit
Study NCT06450249 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-administered questionnaire
Description: The self-administered questionnaire will be completed before and after participation in Humanitude® Care Methodology training sessions
Study NCT04021199 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mody test
Description: Subjects will be screened using a MODY gene-sequencing test, which includes GCK, HNF1A, HNF4A, HNF1B, KCNJ11, ABCC8, and INS gene sequencing.~More comprehensive genetic tests will be conducted in patients without anomalies found after the MODY gene-sequencing test.
Study NCT04021199 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Mody test
Description: Subjects will be screened using a MODY gene-sequencing test, which includes GCK, HNF1A, HNF4A, HNF1B, KCNJ11, ABCC8, and INS gene sequencing.~More comprehensive genetic tests will be conducted in patients without anomalies found after the MODY gene-sequencing test.
Study NCT02704546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: oral capsules (per os) each containing 10mg Methylphenidate.
Study NCT02704546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
Study NCT04942795 — intervention group
Intervention type: DEVICE
Intervention: Compliant balloon
Description: Use of a compliant balloon when ADAPT fails to reach the clot site
Study NCT04202770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exosomes
Description: Focused ultrasound delivery of intravenously-infused exosomes
Study NCT03420794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy
Description: Patients will be screened, enrolled, consented, and randomized during the preoperative office encounter, typically occurring within the 30 days prior to surgery. Patients randomized to pre-admission administration (study group) will be provided with a prescription for a one-time dosing of routine oral non-narcotic analgesic medications to be filled at the Cleveland Clinic outpatient pharmacy. Both the study and the control groups will receive written pre-operative instructions. Those patients randomized to the standard practice of administration in the pre-anesthesia unit (control group) will be administered the same medications in the same doses by the nursing staff. Patients in both groups will undergo general anesthesia, orogastric tube placement, and minimally invasive hysterectomy (MIH). Postoperatively, these patients will be observed for differences in PACU narcotic uptake, pain scores, patient satisfaction, and surgical recovery.
Study NCT03420794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy
Description: Patients will be screened, enrolled, consented, and randomized during the preoperative office encounter, typically occurring within the 30 days prior to surgery. Patients randomized to pre-admission administration (study group) will be provided with a prescription for a one-time dosing of routine oral non-narcotic analgesic medications to be filled at the Cleveland Clinic outpatient pharmacy. Both the study and the control groups will receive written pre-operative instructions. Those patients randomized to the standard practice of administration in the pre-anesthesia unit (control group) will be administered the same medications in the same doses by the nursing staff. Patients in both groups will undergo general anesthesia, orogastric tube placement, and minimally invasive hysterectomy (MIH). Postoperatively, these patients will be observed for differences in PACU narcotic uptake, pain scores, patient satisfaction, and surgical recovery.
Study NCT01628445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: liraglutide titrated to 1.8 mg sc daily
Study NCT01628445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: placebo injected sc daily volume equal to active comparator
Study NCT00693914 — intervention group
Intervention type: BEHAVIORAL
Intervention: Series of tests/questionnaires
Description: Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
Study NCT03422562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Florababy
Description: Probiotic supplement
Study NCT00853398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical technique
Study NCT00853398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical technique
Study NCT03947983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensor-controlled digital game (SCDG)
Description: The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors.
Study NCT03947983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensor Only
Description: Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
Study NCT02545621 — intervention group
Intervention type: OTHER
Intervention: RAGE TXNIP Inflammasome axis
Study NCT01997762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: gel-coated capsules to be taken twice a day; one with breakfast and dinner
Study NCT01997762 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01007032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Cixutumumab intravenously
Study NCT03823404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COR388 capsule
Description: BID (twice daily)
Study NCT03823404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: BID
Study NCT03035695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axiostat®
Study NCT00734500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
Study NCT03035695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton Gauze
Study NCT03461172 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery of breast cancer
Description: Surgery of breast cancer
Study NCT03461172 — intervention group
Intervention type: OTHER
Intervention: Clinical data collection
Description: The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
Study NCT00931242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
Study NCT03720899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicoBloc
Description: For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
Study NCT03720899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Lozenge
Description: Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
Study NCT03858842 — intervention group
Intervention type: OTHER
Intervention: epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD
Description: epidemiology, characteristics, healthcare resources and associated costs of patients diagnosed with non-IPF PF-ILD and SSc-ILD
Study NCT02508142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine-N-Butylbromide
Description: Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute
Study NCT02508142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyoscine-N-Butylbromide
Description: Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute
Study NCT02730273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trial Nasal mask
Description: Nasal mask for the treatment of obstructive sleep apnea (OSA)
Study NCT00884325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine dihydrochloride (Xyzal)
Description: One tablet 5 mg taken orally at night for 28 days
Study NCT00884325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One tablet taken orally at night for 28 days
Study NCT06188819 — intervention group
Intervention type: PROCEDURE
Intervention: Explantation of a previous aortic graft or endograft and reconstruction by arterial allograft or rolled pericardium
Description: In situ reconstruction with explantation of the infected graft or endograft and reconstruction by allograft or pericardium
Study NCT01434550 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
Study NCT01434550 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Tissue, Blood, Research Imaging (TBRI)
Description: Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess~1. Necrosis/apoptosis~2. Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)~1. Aposense-PET imaging
Study NCT00290290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine-alcohol
Description: Preoperative skin preparation with scrub and paint technique
Study NCT00290290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: preoperative skin preparation with scrub and paint technique
Study NCT03483909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left IFG iTBS
Description: 15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4
Study NCT03483909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: right IPL cTBS
Description: 15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4
Study NCT03483909 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL
Study NCT02757508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein powder supplement
Study NCT02124395 — intervention group
Intervention type: OTHER
Intervention: Health-related Quality of Life in Rare Kidney Stone Questionnaire
Study NCT03585985 — intervention group
Intervention type: PROCEDURE
Intervention: Standard patient monitor
Description: Measurement of reference data: heart rate, heart rate variability and respiratory rate
Study NCT03585985 — intervention group
Intervention type: PROCEDURE
Intervention: Photoplethysmographie-Imaging (PPGI) + Infrared thermography (IRT)
Description: Camera-based technology for the determination of heart rate variability (PPGI) and contactless measurement of breathing rate (IRT)
Study NCT02525055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious titre 1 (H3N2)
Description: Infectious titre 1: 2.8 x 10\*3 TCID50/mL
Study NCT02525055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious titre 2 (H3N2)
Description: Infectious titre 2: 2.5 x 10\*4 TCID50/mL
Study NCT02525055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious titre 3 (H3N2)
Description: Infectious titre 3: 3.6 x 10\*5 TCID50/mL
Study NCT02525055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious titre 4 (H3N2)
Description: Infectious titre 4: 4.7 x 10\*6 TCID50/mL
Study NCT02525055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious titre 5 (H3N2) (Subjects aged 18 to 45 years old)
Description: Infectious titre 5: 3.5 x 10\*5 TCID50/mL
Study NCT02525055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious titre 5 (H3N2) (Subjects aged 46 to 64 years old)
Description: Infectious titre 5: 3.5 x 10\*5 TCID50/mL
Study NCT01211535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE RepleniSH multipurpose solution
Description: FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
Study NCT01211535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReNu Biotrue multipurpose solution
Description: FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
Study NCT01211535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone hydrogel contact lenses
Description: Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
Study NCT01211535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone hydrogel contact lenses
Description: Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
Study NCT04013789 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DACP FreshTech contact lenses
Description: Nelfilcon A soft contact lenses with a modified lens design
Study NCT04013789 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DACP contact lenses
Description: Nelfilcon A soft contact lenses
Study NCT01247987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blastocyst cryopreservation
Description: Embryos cryopreserved at the blastocyst stage
Study NCT01247987 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipronuclear oocyte cryopreservation
Description: Bipronuclear oocyte cryopreservation.
Study NCT02342496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder
Study NCT02342496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active, only probiotics
Description: Powder
Study NCT02342496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active, blend of berries and probiotics
Description: Powder
Study NCT00670501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
Study NCT00670501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
Study NCT00670501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
Study NCT00670501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Supplement
Description: Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
Study NCT00670501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Supplement
Description: Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
Study NCT00670501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplement
Description: Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement